Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Active not recruiting 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 1Salivary Gland Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1

Interventions

Carboplatin 235Pemetrexed 214Paclitaxel 160Cisplatin 150pembrolizumab 145Erlotinib Hydrochloride 141Docetaxel 133Gemcitabine 94Bevacizumab 85Nivolumab 72Radiotherapy 62atezolizumab 40Radiosurgery 37Afatinib 37osimertinib 35130-nm albumin-bound paclitaxel 35Cetuximab 34durvalumab 33Ipilimumab 32Gefitinib 31Albumin-Bound Paclitaxel 29Vinorelbine 23Taxes 22Etoposide 20Crizotinib 19Radiation 17Sorafenib 16Cyclophosphamide 16Dexamethasone 15Magnetic Resonance Spectroscopy 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Carcinoma, Non-Small-Cell Lung × amivantamab × Clear all
NCT05663866 2026-06-02

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Janssen Research & Development, LLC

Phase 2 Active not recruiting
68 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Janssen Research & Development, LLC

Phase 3 Active not recruiting
1,074 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-05-08

PAPILLON

Janssen Research & Development, LLC

Phase 3 Active not recruiting
308 enrolled 12 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Janssen Research & Development, LLC

Phase 3 Active not recruiting
776 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-05-08

PALOMA-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
418 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡